Zolpidem (Stilnox) in Personal Injury Claims

Managing Z-drug risk in workers compensation and personal injury recovery

Published: 3 April 2026 | Updated: 3 April 2026

The Zolpidem Dilemma in Claims

Zolpidem (Stilnox) is a non-benzodiazepine hypnotic widely prescribed in Australia and New Zealand for insomnia, particularly in injured claimants experiencing sleep disruption secondary to pain, anxiety, or stress. On the surface, it seems reasonable: injury causes insomnia, zolpidem restores sleep, claimant recovers. In practice, zolpidem use in claims frequently becomes problematic. Claimants remain on the medication long-term, dependence emerges, and sleep dysregulation persists even after pain resolves. Your challenge is balancing the genuine need for sleep support with the real risk of iatrogenic dependence and delayed recovery.

This article equips you to identify when zolpidem use supports claims recovery and when it becomes a barrier to it.

What Is Zolpidem and How Does It Work

Zolpidem is a selective benzodiazepine receptor agonist that acts on GABA receptors in the central nervous system. Unlike traditional benzodiazepines, it has minimal muscle relaxant or anxiolytic properties; it's designed specifically to initiate sleep. It works quickly, usually within 15 to 30 minutes, with a half-life of 2.5 to 3 hours in standard formulation. Extended-release formulations (Stilnox CR) are also available, providing sustained sleep maintenance.

In theory, this targeted mechanism means fewer side effects than benzodiazepines. In claims practice, claimants still develop psychological and physiological dependence, and discontinuation is often difficult.

Why Zolpidem Becomes Problematic in Claims

Dependence Development

Physical and psychological dependence on zolpidem can emerge within 1 to 2 weeks of regular use. Some claimants don't perceive themselves as dependent because zolpidem isn't "recreational"; they're simply following prescriber instructions. After 3 or 6 months, attempting to cease or reduce triggers rebound insomnia, anxiety, and sometimes perceptual disturbances. This rebound often leads prescribers to reinstate the medication, reinforcing the cycle.

Sleep Architecture Disruption

Zolpidem chemically induces sleep but doesn't restore normal sleep architecture. Claimants may sleep 8 hours yet report feeling unrefreshed. This paradox frustrates both claimant and prescriber, leading to dose escalation or addition of other sleep aids. Meanwhile, the underlying sleep dysregulation isn't addressed, just masked.

Cognitive and Functional Impairment

Zolpidem carries significant next-day impairment risk. Some claimants report residual drowsiness, poor concentration, or memory lapses the morning after a dose. For return-to-work planning, this is critical. A claimant on nightly zolpidem may be unsafe to drive or perform safety-sensitive duties. Many insurers underestimate this risk and approve return-to-work while claimants remain on hypnotics.

Complex Behavior During Sleep

Rare but serious: some individuals experience complex sleep behaviors, including sleep-walking, sleep-eating, or driving, without conscious awareness. These are more common at higher doses or with concurrent CNS depressants. While uncommon, they create significant liability risk in claims, particularly if the claimant is injured while engaging in these behaviors.

Zolpidem Risk Assessment for Claims

Zolpidem and Return-to-Work Planning

Never approve return-to-work while the claimant is on regular zolpidem without explicit assessment of work-readiness. A claimant on nightly zolpidem may be cognitively impaired or fatigued the following day. If the role involves machinery operation, driving, or safety-critical tasks, the claimant is at elevated risk.

Your claims process should include a mandatory occupational health and safety review if return-to-work is contemplated while the claimant remains on zolpidem. This review should address:

• Expected cognitive and motor impairment from zolpidem on the day shift
• Whether the role can be modified to accommodate impairment
• Timeline for zolpidem cessation prior to full duties resumption
• Alternatives to zolpidem: CBT-I, sleep hygiene, or non-hypnotic options

Deprescribing Zolpidem in Claims

Abrupt cessation of zolpidem after prolonged use causes rebound insomnia, which is often severe and demoralizing. Claimants frequently reinitiate the medication themselves or demand it from prescribers. Responsible deprescribing requires planning and support:

Supporting Deprescribing

Successful cessation requires coordinated care. Your role as an insurer is to support this process, not undermine it. This means:

• Funding cognitive-behavioural therapy for insomnia (CBT-I), which has strong evidence for sustained sleep improvement post-hypnotic cessation
• Ensuring the prescriber has a documented deprescribing plan before zolpidem cessation begins
• Monitoring claimant progress; if they reinitiate without authorization, escalate to case management
• Avoiding pressure to resume zolpidem if rebound insomnia emerges in the first 2 weeks post-cessation

Alternative Sleep Management Strategies

For acute insomnia secondary to injury, consider these alternatives to zolpidem or early interventions to prevent long-term use:

Melatonin and Melatonin Agonists

Melatonin (2 to 5mg at bedtime) or ramelteon (8mg at bedtime) support circadian rhythm regulation without dependence risk. These are particularly useful if sleep disruption is tied to injury-related schedule changes or hospital stays.

Low-Dose Tricyclic Antidepressants

Amitriptyline 10 to 25mg at bedtime combines sleep support with mood benefit and pain modulation. No dependence risk. Useful in claimants with concurrent depression or chronic pain-related insomnia.

CBT-I

Cognitive-behavioural therapy for insomnia addresses the psychological perpetuators of sleep disruption. Guidelines now recommend CBT-I as first-line for chronic insomnia. Combined with pharmacological support initially, CBT-I enables sustained improvement and medication cessation.

Your Role in Zolpidem Governance

You're not preventing claimants from accessing zolpidem when genuinely needed; you're ensuring it's used responsibly and time-limited. This means:

• Initial prescription: Approve short-term use (2 to 4 weeks) for acute post-injury insomnia without requiring a review.
• At 8 weeks: Request pharmacy review. Why is the claimant still on zolpidem? Is sleep improving? Are there barriers to cessation?
• At 16 weeks: If still on zolpidem, mandatory deprescribing plan must be documented. No further extensions without justification.
• Return-to-work planning: Mandatory assessment of zolpidem's impact on work-readiness and occupational health safety.
• Funding deprescribing: Invest in CBT-I, sleep hygiene counseling, or behavioral sleep medicine to support successful cessation.